Victoza has just given Novo Nordisk a boost, with new data showing it can cut the risk of heart attacks, strokes and cardiovascular death in type 2 diabetes patients. The five-year LEADER study of ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of drugs that are allowed to be compounded. In a Citizen Petition posted on ...

Novo Nordisk also announced encouraging phase 3 data from its investigational drug semaglutide, which like Victoza is a GLP-1 class drug, but can be administered by injection weekly, not daily.

Against a backdrop of manufacturing prioritisation, Novo ... pen needles market. The needle device market is forecast to grow to over $6.8bn by 2033, according to analysis by GlobalData. Novo ...

BURLINGAME, CA, UNITED STATES, January 14, 2025 /EINPresswire / -- The Pen Needles Market Report is the result of extensive research and analysis conducted by our team of experienced market ...

To hear Novo tell it, the outsourcing group OFA shouldn’t be allowed to place liraglutide on its compounding list given that FDA-approved generics to Victoza are available. Further, the OFA has ...